Bapineuzumab does not improve clinical outcomes in Alzheimer’s disease
Image: PD 1. Bapineuzumab, a humanized anti-Aβ monoclonal antibody, did not improve clinical outcomes in patients with mild-to-moderate Alzheimer’s disease. ...
Image: PD 1. Bapineuzumab, a humanized anti-Aβ monoclonal antibody, did not improve clinical outcomes in patients with mild-to-moderate Alzheimer’s disease. ...
Image: PD 1. Solanezumab did not improve cognition or functional ability in mild-to-moderate Alzheimer’s disease at week 80. 2. Solanezumab ...
Image: PD/Tau Protein Alzheimer Disease In this section, we will highlight the key high-impact studies, updates, and analyses published in ...
Image: PD 1. Vitamin E supplementation was associated with decrease in the rate of loss in activities of daily living ...
Image: PD 1. Amyloid plaques, similar to those found in Alzheimer’s disease were found in traumatic brain injury (TBI) victims. ...
Image: PD 1. Use of semagacestat was associated with dose-relevant clinical worsening. 2. There were also renal and immunologic effects ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.